BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rossi E, Adams L, Prins A, Bulsara M, de Boer B, Garas G, MacQuillan G, Speers D, Jeffrey G. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem. 2003;49:450-454. [PMID: 12600957 DOI: 10.1373/49.3.450] [Cited by in Crossref: 166] [Cited by in F6Publishing: 159] [Article Influence: 8.7] [Reference Citation Analysis]
Number Citing Articles
1 Herrine SK, Friedman LS. Divining the role of liver biopsy in hepatitis C. J Hepatol. 2005;43:374-376. [PMID: 16046025 DOI: 10.1016/j.jhep.2005.06.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
2 Poynard T, Morra R, Ingiliz P, Imbert-Bismut F, Thabut D, Messous D, Munteanu M, Massard J, Benhamou Y, Ratziu V. Biomarkers of liver fibrosis. Adv Clin Chem. 2008;46:131-160. [PMID: 19004189 DOI: 10.1016/s0065-2423(08)00404-6] [Cited by in Crossref: 46] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
3 Adams LA. Biomarkers of liver fibrosis. J Gastroenterol Hepatol. 2011;26:802-809. [PMID: 21198831 DOI: 10.1111/j.1440-1746.2010.06612.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 5.9] [Reference Citation Analysis]
4 Kelleher TB, Afdhal N. Noninvasive Assessment of Liver Fibrosis. Clinics in Liver Disease 2005;9:667-83. [DOI: 10.1016/j.cld.2005.08.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
5 Dufour DR. Assessment of liver fibrosis: Can serum become the sample of choice. Clin Chem. 2005;51:1763-1764. [PMID: 16189374 DOI: 10.1373/clinchem.2005.056929] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
6 Thuluvath PJ, Krok KL. Noninvasive markers of fibrosis for longitudinal assessment of fibrosis in chronic liver disease: are they ready for prime time. Am J Gastroenterol. 2005;100:1981-1983. [PMID: 16128942 DOI: 10.1111/j.1572-0241.2005.00284.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sanai FM, Keeffe EB. Liver biopsy for histological assessment: The case against. Saudi J Gastroenterol. 2010;16:124-132. [PMID: 20339187 DOI: 10.4103/1319-3767.61244] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
8 Chrostek L, Panasiuk A. Liver fibrosis markers in alcoholic liver disease. World J Gastroenterol 2014; 20(25): 8018-8023 [PMID: 25009372 DOI: 10.3748/wjg.v20.i25.8018] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
9 Wong GL. Prediction of fibrosis progression in chronic viral hepatitis. Clin Mol Hepatol 2014;20:228-36. [PMID: 25320725 DOI: 10.3350/cmh.2014.20.3.228] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
10 Lichtinghagen R, Bahr MJ. Noninvasive diagnosis of fibrosis in chronic liver disease. Expert Rev Mol Diagn. 2004;4:715-726. [PMID: 15347264 DOI: 10.1586/14737159.4.5.715] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 1.8] [Reference Citation Analysis]
11 Poon TC, Hui AY, Chan HL, Ang IL, Chow SM, Wong N, Sung JJ. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin Chem. 2005;51:328-335. [PMID: 15590748 DOI: 10.1373/clinchem.2004.041764] [Cited by in Crossref: 101] [Cited by in F6Publishing: 91] [Article Influence: 5.6] [Reference Citation Analysis]
12 Fowell AJ, Iredale JP. Emerging therapies for liver fibrosis. Dig Dis. 2006;24:174-183. [PMID: 16699275 DOI: 10.1159/000090320] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 3.1] [Reference Citation Analysis]
13 Imbert-Bismut F, Messous D, Thibault V, Myers RB, Piton A, Thabut D, Devers L, Hainque B, Mercadier A, Poynard T. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med. 2004;42:323-333. [PMID: 15080567 DOI: 10.1515/cclm.2004.058] [Cited by in Crossref: 62] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
14 Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, de Lédinghen V. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-50. [DOI: 10.1053/j.gastro.2004.11.018] [Cited by in Crossref: 1666] [Cited by in F6Publishing: 1579] [Article Influence: 98.0] [Reference Citation Analysis]
15 Patel K, Gordon SC, Jacobson I, Hézode C, Oh E, Smith KM, Pawlotsky J, Mchutchison JG. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. Journal of Hepatology 2004;41:935-42. [DOI: 10.1016/j.jhep.2004.08.008] [Cited by in Crossref: 231] [Cited by in F6Publishing: 216] [Article Influence: 12.8] [Reference Citation Analysis]
16 Cholongitas E, Senzolo M, Standish R, Marelli L, Quaglia A, Patch D, Dhillon AP, Burroughs AK. A systematic review of the quality of liver biopsy specimens. Am J Clin Pathol. 2006;125:710-721. [PMID: 16707372 DOI: 10.1309/w3xcnt4hkfbn2g0b] [Cited by in Crossref: 151] [Cited by in F6Publishing: 4] [Article Influence: 9.4] [Reference Citation Analysis]
17 Ahmad W, Ijaz B, Gull S, Asad S, Khaliq S, Jahan S, Sarwar MT, Kausar H, Sumrin A, Shahid I. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Virol J. 2011;8:53. [PMID: 21299910 DOI: 10.1186/1743-422x-8-53] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
18 Saiz de la Hoya-zamácola P, Marco-mouriño A, Clemente-ricote G, Portilla-sogorb J, Boix-martínez V, Núñez-martínez Ó, Reus-bañuls S, Teixidó i Pérez N. Recomendaciones de expertos sobre el diagnóstico y tratamiento de la hepatitis C crónica en el medio penitenciario. Gastroenterología y Hepatología 2006;29:551-9. [DOI: 10.1157/13094351] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
19 Bissell DM. Assessing fibrosis without a liver biopsy: are we there yet. Gastroenterology. 2004;127:1847-1849. [PMID: 15578524 DOI: 10.1053/j.gastro.2004.10.012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
20 Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, Kench J, Farrell G, McCaughan GW, Jeffrey GP. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem. 2005;51:1867-1873. [PMID: 16055434 DOI: 10.1373/clinchem.2005.048389] [Cited by in Crossref: 362] [Cited by in F6Publishing: 330] [Article Influence: 21.3] [Reference Citation Analysis]
21 Gangadharan B, Antrobus R, Dwek RA, Zitzmann N. Novel serum biomarker candidates for liver fibrosis in hepatitis C patients. Clin Chem. 2007;53:1792-1799. [PMID: 17702858 DOI: 10.1373/clinchem.2007.089144] [Cited by in Crossref: 114] [Cited by in F6Publishing: 108] [Article Influence: 7.6] [Reference Citation Analysis]
22 Adams PC, Arthur MJ, Boyer TD, DeLeve LD, Di Bisceglie AM, Hall M, Levin TR, Provenzale D, Seeff L. Screening in liver disease: report of an AASLD clinical workshop. Hepatology. 2004;39:1204-1212. [PMID: 15122748 DOI: 10.1002/hep.20169] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
23 Kadam JS, Talal AH. Changing treatment paradigms: hepatitis C virus in HIV-infected patients. AIDS Patient Care STDS 2007;21:154-68. [PMID: 17428183 DOI: 10.1089/apc.2006.0126] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
24 Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol. 2004;99:1160-1174. [PMID: 15180741 DOI: 10.1111/j.1572-0241.2004.30110.x] [Cited by in Crossref: 400] [Cited by in F6Publishing: 374] [Article Influence: 22.2] [Reference Citation Analysis]
25 Zarski J, Bedossa P, Bronowicki J, Doffoel M, Poynard T. Utilisation des marqueurs non invasifs de fibrose dans la prise en charge de l’hépatite C. Gastroentérologie Clinique et Biologique 2007;31:34-9. [DOI: 10.1016/s0399-8320(07)92561-0] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
26 Alswat KA, Mumtaz K, Jafri W. Liver biopsy for histological assessment: The case in favor. Saudi J Gastroenterol 2010;16:133-9. [PMID: 20339188 DOI: 10.4103/1319-3767.61245] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
27 Vallet-pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-venier V, Fontaine H, Pol S. FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007;46:32-6. [DOI: 10.1002/hep.21669] [Cited by in Crossref: 1026] [Cited by in F6Publishing: 981] [Article Influence: 68.4] [Reference Citation Analysis]
28 Cross T, Antoniades C, Harrison P. Non-invasive markers for the prediction of fibrosis in chronic hepatitis C infection. Hepatol Res 2008;38:762-9. [PMID: 18462378 DOI: 10.1111/j.1872-034X.2008.00364.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
29 Stasi C, Arena U, Vizzutti F, Zignego AL, Monti M, Laffi G, Corti G, Pinzani M. Transient elastography for the assessment of liver fibrosis in patients with chronic viral hepatitis: the missing tool? Dig Liver Dis. 2009;41:863-866. [PMID: 19482565 DOI: 10.1016/j.dld.2009.04.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
30 Crockett SD, Kaltenbach T, Keeffe EB. Do We Still Need a Liver Biopsy? Are the Serum Fibrosis Tests Ready for Prime Time? Clinics in Liver Disease 2006;10:513-34. [DOI: 10.1016/j.cld.2006.08.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
31 Gökçe S, Sökücü S. Utility of noninvasive markers of liver injury. J Pediatr Gastroenterol Nutr 2010;51:685-6. [PMID: 20978420 DOI: 10.1097/MPG.0b013e3181ea7456] [Reference Citation Analysis]
32 Saiz de la Hoya-Zamácola P, Marco-Mouriño A, Clemente-Ricote G, Portilla-Sogorb J, Boix-Martínez V, Núñez-Martínez O, Reus-Bañuls S, Teixidó i Pérez N. [Expert recommendations for the diagnosis and treatment of chronic hepatitis C infection in the prison setting]. Enferm Infecc Microbiol Clin 2006;24:568-75. [PMID: 17125677 DOI: 10.1157/13093878] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
33 Hsieh YY, Tung SY, Lee K, Wu CS, Wei KL, Shen CH, Chang TS, Lin YH. Routine blood tests to predict liver fibrosis in chronic hepatitis C. World J Gastroenterol 2012; 18(8): 746-753 [PMID: 22371634 DOI: 10.3748/wjg.v18.i8.746] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
34 Sethi S, Simonetto DA, Abdelmoneim SS, Campion MB, Kaloiani I, Clayton AC, Kremers WK, Halling KC, Kamath PS, Talwalkar J, Shah VH. Comparison of circulating endothelial cell/platelet count ratio to aspartate transaminase/platelet ratio index for identifying patients with cirrhosis. J Clin Exp Hepatol 2012;2:19-26. [PMID: 25755402 DOI: 10.1016/S0973-6883(12)60078-4] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
35 Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology 2006;43:S113-20. [DOI: 10.1002/hep.21046] [Cited by in Crossref: 221] [Cited by in F6Publishing: 210] [Article Influence: 13.8] [Reference Citation Analysis]
36 Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology. 2008;134:1670-1681. [PMID: 18471546 DOI: 10.1053/j.gastro.2008.03.001] [Cited by in Crossref: 289] [Cited by in F6Publishing: 271] [Article Influence: 20.6] [Reference Citation Analysis]
37 Ceylan B, Mete B, Fincanci M, Aslan T, Akkoyunlu Y, Ozguneş N, Colak O, Gunduz A, Senates E, Ozaras R. A new model using platelet indices to predict liver fibrosis in patients with chronic hepatitis B infection. Wien Klin Wochenschr. 2013;125:453-460. [PMID: 23860694 DOI: 10.1007/s00508-013-0394-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
38 Chrostek L, Przekop D, Gruszewska E, Gudowska-Sawczuk M, Cylwik B. Noninvasive Indirect Markers of Liver Fibrosis in Alcoholics. Biomed Res Int 2019;2019:3646975. [PMID: 31192254 DOI: 10.1155/2019/3646975] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Chrysanthos NV, Papatheodoridis GV, Savvas S, Kafiri G, Petraki K, Manesis EK, Archimandritis AJ. Aspartate aminotransferase to platelet ratio index for fibrosis evaluation in chronic viral hepatitis: . European Journal of Gastroenterology & Hepatology 2006;18:389-96. [DOI: 10.1097/00042737-200604000-00012] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
40 Poynard T, Zoulim F, Ratziu V, Degos F, Imbert-Bismut F, Deny P, Landais P, El Hasnaoui A, Slama A, Blin P. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol. 2005;100:1970-1980. [PMID: 16128941 DOI: 10.1111/j.1572-0241.2005.41957.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 79] [Article Influence: 4.7] [Reference Citation Analysis]
41 Forns X, Bataller R. Can we identify liver fibrosis in HCV-infected patients without a liver biopsy? Curr hepatitis rep 2003;2:145-51. [DOI: 10.1007/s11901-003-0016-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
42 Smith MA, Mohammad RA. Ledipasvir-sofosbuvir for hepatitis C genotype 4 infection. Lancet Infect Dis 2015;15:993-5. [PMID: 26187029 DOI: 10.1016/S1473-3099(15)00223-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
43 Goldstein NS, Hastah F, Galan MV, Gordon SC. Fibrosis heterogeneity in nonalcoholic steatohepatitis and hepatitis C virus needle core biopsy specimens. Am J Clin Pathol. 2005;123:382-387. [PMID: 15716234 DOI: 10.1309/ey72f1en9xcb1kxx] [Cited by in Crossref: 66] [Cited by in F6Publishing: 1] [Article Influence: 3.9] [Reference Citation Analysis]
44 Liu S, Schwarzinger M, Carrat F, Goldhaber-Fiebert JD. Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients. PLoS One. 2011;6:e26783. [PMID: 22164204 DOI: 10.1371/journal.pone.0026783] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
45 Belinsky GS, Parke AL, Huang Q, Blanchard K, Jayadev S, Stoll R, Rothe M, Achenie LEK, Gupta RR, Wu GY, Rosenberg DW. The Contribution of Methotrexate Exposure and Host Factors on Transcriptional Variance in Human Liver. Toxicological Sciences 2007;97:582-94. [DOI: 10.1093/toxsci/kfm067] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
46 Castera L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat. 2009;16:300-314. [PMID: 19254351 DOI: 10.1111/j.1365-2893.2009.01087.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 110] [Article Influence: 8.7] [Reference Citation Analysis]
47 Suk KT, Kim DY, Sohn KM, Kim DJ. Biomarkers of liver fibrosis. Adv Clin Chem 2013;62:33-122. [PMID: 24772665 DOI: 10.1016/b978-0-12-800096-0.00002-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
48 Huang H, Wu T, Mao J, Fang Y, Zhang J, Wu L, Zheng S, Lin B, Pan H. CHI3L1 Is a Liver-Enriched, Noninvasive Biomarker That Can Be Used to Stage and Diagnose Substantial Hepatic Fibrosis. OMICS. 2015;19:339-345. [PMID: 26415140 DOI: 10.1089/omi.2015.0037] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
49 Lau-Corona D, Pineda LA, Avilés HH, Gutiérrez-Reyes G, Farfan-Labonne BE, Núñez-Nateras R, Bonder A, Martínez-García R, Corona-Lau C, Olivera-Martínez MA, Gutiérrez-Ruiz MC, Robles-Díaz G, Kershenobich D. Effective use of FibroTest to generate decision trees in hepatitis C. World J Gastroenterol 2009; 15(21): 2617-2622 [PMID: 19496191 DOI: 10.3748/wjg.15.2617] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
50 Coco B, Oliveri F, Maina AM, Ciccorossi P, Sacco R, Colombatto P, Bonino F, Brunetto MR. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat. 2007;14:360-369. [PMID: 17439526 DOI: 10.1111/j.1365-2893.2006.00811.x] [Cited by in Crossref: 461] [Cited by in F6Publishing: 435] [Article Influence: 30.7] [Reference Citation Analysis]
51 Cadranel J, Castera L, Cales P. La ponction biopsie du foie dans le diagnostic et la prise en charge des maladies chroniques du foie. Gastroentérologie Clinique et Biologique 2006;30:121-3. [DOI: 10.1016/s0399-8320(06)73126-8] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
52 Smyth R, Lane CS, Ashiq R, Turton JA, Clarke CJ, Dare TO, York MJ, Griffiths W, Munday MR. Proteomic investigation of urinary markers of carbon-tetrachloride-induced hepatic fibrosis in the Hanover Wistar rat. Cell Biol Toxicol 2009;25:499-512. [DOI: 10.1007/s10565-008-9104-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
53 Luxon BA. Noninvasive tests for liver fibrosis. Postgrad Med 2006;119:8-13. [PMID: 17128639 DOI: 10.1080/00325481.2006.11446044] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
54 Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, Naveau S, Thabut D, Lebrec D, Zoulim F, Bourliere M, Cacoub P, Messous D, Munteanu M, de Ledinghen V. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol. 2007;7:40. [PMID: 17937811 DOI: 10.1186/1471-230x-7-40] [Cited by in Crossref: 205] [Cited by in F6Publishing: 75] [Article Influence: 13.7] [Reference Citation Analysis]
55 Kelleher TB, Afdhal N. Assessment of liver fibrosis in co-infected patients. J Hepatol 2006;44:S126-31. [PMID: 16352364 DOI: 10.1016/j.jhep.2005.11.026] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
56 Sohrabpour AA, Mohamadnejad M, Malekzadeh R. Review article: the reversibility of cirrhosis. Aliment Pharmacol Ther 2012;36:824-32. [PMID: 22966946 DOI: 10.1111/apt.12044] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
57 Yan FR, Lin JG, Liu Y. Sparse logistic regression for diagnosis of liver fibrosis in rat by using SCAD-penalized likelihood. J Biomed Biotechnol 2011;2011:875309. [PMID: 21716672 DOI: 10.1155/2011/875309] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
58 Sebastiani G, Vario A, Guido M, Noventa F, Plebani M, Pistis R, Ferrari A, Alberti A. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol. 2006;44:686-693. [PMID: 16490278 DOI: 10.1016/j.jhep.2006.01.007] [Cited by in Crossref: 193] [Cited by in F6Publishing: 171] [Article Influence: 12.1] [Reference Citation Analysis]
59 Liu T, Wang X, Karsdal MA, Leeming DJ, Genovese F. Molecular serum markers of liver fibrosis. Biomark Insights. 2012;7:105-117. [PMID: 22872786 DOI: 10.4137/bmi.s10009] [Cited by in Crossref: 76] [Cited by in F6Publishing: 43] [Article Influence: 7.6] [Reference Citation Analysis]
60 Maurice P, Maddox A, Green C, Tatnall F, Schofield J, Stott D. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen. Br J Dermatol 2005;152:451-8. [DOI: 10.1111/j.1365-2133.2005.06459.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
61 Zeremski M, Dimova RB, Benjamin S, Makeyeva J, Yantiss RK, Gambarin-Gelwan M, Talal AH. FibroSURE as a noninvasive marker of liver fibrosis and inflammation in chronic hepatitis B. BMC Gastroenterol 2014;14:118. [PMID: 24990385 DOI: 10.1186/1471-230X-14-118] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
62 Park SH, Kim DJ, Cheong JY, Cho SW, Hwang SG, Lee YJ, Cho M, Yang JM, Kim YB. Noninvasive markers to diagnose cirrhosis in patients with HBeAg positive chronic hepatitis: Do new biomarkers improve the accuracy? Clinical Biochemistry 2010;43:877-81. [DOI: 10.1016/j.clinbiochem.2010.04.063] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
63 Yokoo T, Wolfson T, Iwaisako K, Peterson MR, Mani H, Goodman Z, Changchien C, Middleton MS, Gamst AC, Mazhar SM, Kono Y, Ho SB, Sirlin CB. Evaluation of Liver Fibrosis Using Texture Analysis on Combined-Contrast-Enhanced Magnetic Resonance Images at 3.0T. Biomed Res Int 2015;2015:387653. [PMID: 26421287 DOI: 10.1155/2015/387653] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
64 Halfon P, Bourliere M, Deydier R, Botta-fridlund D, Renou C, Tran A, Portal I, Allemand I, Bertrand JJ, Rosenthal-allieri A, Rotily M, Sattonet C, Benderitter T, Paul MCS, Bonnot HP, Penaranda G, Degott C, Masseyeff MF, Ouzan D. Independent Prospective Multicenter Validation of Biochemical Markers (Fibrotest-Actitest) for the Prediction of Liver Fibrosis and Activity in Patients with Chronic Hepatitis C: The Fibropaca Study. Am J Gastroenterology 2006;101:547-55. [DOI: 10.1111/j.1572-0241.2006.00411.x] [Cited by in Crossref: 98] [Cited by in F6Publishing: 99] [Article Influence: 6.1] [Reference Citation Analysis]
65 Jiang Z, Yamauchi K, Yoshioka K, Aoki K, Kuroyanagi S, Iwata A, Yang J, Wang K. Support Vector Machine-Based Feature Selection for Classification of Liver Fibrosis Grade in Chronic Hepatitis C. J Med Syst 2006;30:389-94. [DOI: 10.1007/s10916-006-9023-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
66 Lim AK, Taylor-Robinson SD, Patel N, Eckersley RJ, Goldin RD, Hamilton G, Foster GR, Thomas HC, Cosgrove DO, Blomley MJ. Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut. 2005;54:128-133. [PMID: 15591518 DOI: 10.1136/gut.2003.030965] [Cited by in Crossref: 106] [Cited by in F6Publishing: 94] [Article Influence: 6.2] [Reference Citation Analysis]
67 Poynard T, Imbert-bismut F, Munteanu M, Messous D, Thabut D, Ratziu V, Benhamou Y. Biomarkers as non-invasive assessment of hepatic fibrosis in chronic hepatitis C. J Gastroenterol Hepatol 2004;19:S236-45. [DOI: 10.1111/j.1440-1746.2004.03680.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
68 Lalazar G, Pappo O, Hershcovici T, Hadjaj T, Shubi M, Ohana H, Hemed N, Ilan Y. A continuous 13C methacetin breath test for noninvasive assessment of intrahepatic inflammation and fibrosis in patients with chronic HCV infection and normal ALT. J Viral Hepat. 2008;15:716-728. [PMID: 18638013 DOI: 10.1111/j.1365-2893.2008.01007.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
69 Fallowfield JA, Iredale JP. Targeted treatments for cirrhosis. Expert Opin Ther Targets. 2004;8:423-435. [PMID: 15469393 DOI: 10.1517/14728222.8.5.423] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 2.4] [Reference Citation Analysis]
70 Thabut D, Le Calvez S, Thibault V, Massard J, Munteanu M, Di Martino V, Ratziu V, Poynard T. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol. 2006;101:1260-1267. [PMID: 16771947 DOI: 10.1111/j.1572-0241.2006.00556.x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 75] [Article Influence: 5.2] [Reference Citation Analysis]
71 Yang L, Rudser KD, Higgins L, Rosen HR, Zaman A, Corless CL, David L, Gourley GR. Novel biomarker candidates to predict hepatic fibrosis in hepatitis C identified by serum proteomics. Dig Dis Sci. 2011;56:3305-3315. [PMID: 21590334 DOI: 10.1007/s10620-011-1745-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
72 Tawa GJ, AbdulHameed MD, Yu X, Kumar K, Ippolito DL, Lewis JA, Stallings JD, Wallqvist A. Characterization of chemically induced liver injuries using gene co-expression modules. PLoS One 2014;9:e107230. [PMID: 25226513 DOI: 10.1371/journal.pone.0107230] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
73 Karagoz E, Ulcay A, Tanoglu A, Kara M, Turhan V, Erdem H, Oncul O, Gorenek L. Clinical usefulness of mean platelet volume and red blood cell distribution width to platelet ratio for predicting the severity of hepatic fibrosis in chronic hepatitis B virus patients. Eur J Gastroenterol Hepatol. 2014;26:1320-1324. [PMID: 25210777 DOI: 10.1097/meg.0000000000000203] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
74 Crossan C, Tsochatzis EA, Longworth L, Gurusamy K, Davidson B, Rodríguez-Perálvarez M, Mantzoukis K, O’Brien J, Thalassinos E, Papastergiou V. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technol Assess. 2015;19:1-409, v-vi. [PMID: 25633908 DOI: 10.3310/hta19090] [Cited by in Crossref: 84] [Cited by in F6Publishing: 83] [Article Influence: 12.0] [Reference Citation Analysis]
75 Smirne C, Rigamonti C, De Benedittis C, Sainaghi PP, Bellan M, Burlone ME, Castello LM, Avanzi GC. Gas6/TAM Signaling Components as Novel Biomarkers of Liver Fibrosis. Dis Markers 2019;2019:2304931. [PMID: 31583026 DOI: 10.1155/2019/2304931] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
76 Romagnuolo J, Andrews CN, Bain VG, Bonacini M, Cotler SJ, Ma M, Sherman M. Simple clinical variables predict liver histology in hepatitis C: prospective validation of a clinical prediction model. Scand J Gastroenterol 2005;40:1365-71. [PMID: 16334447 DOI: 10.1080/00365520500287400] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
77 Lok ASF, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, Everhart JE, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Dienstag JL, Morishima C; HALT-C Trial Group. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: Results of the HALT-C cohort. Hepatology 2005;42:282-92. [DOI: 10.1002/hep.20772] [Cited by in Crossref: 222] [Cited by in F6Publishing: 207] [Article Influence: 13.1] [Reference Citation Analysis]
78 Ahmed L, Salama H, Ahmed R, Hamdy S, Al-akel W, Shafi SA, Mahgoub A, Hareedy A, Fathy W. Non-invasive fibrosis seromarkers as a predictor of liver fibrosis in chronic hepatitis C and/or non-alcoholic steatohepatitis. Arab Journal of Gastroenterology 2009;10:14-20. [DOI: 10.1016/j.ajg.2009.03.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
79 Boursier J, Dib N, Oberti F, Calès P. Caractéristiques et interprétation des tests sanguins de fibrose hépatique. Gastroentérologie Clinique et Biologique 2007;31:511-23. [DOI: 10.1016/s0399-8320(07)89421-8] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
80 Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006; 12(23): 3682-3694 [PMID: 16773685 DOI: 10.3748/wjg.v12.i23.3682] [Cited by in CrossRef: 174] [Cited by in F6Publishing: 165] [Article Influence: 10.9] [Reference Citation Analysis]
81 Lykiardopoulos B, Hagström H, Fredrikson M, Ignatova S, Stål P, Hultcrantz R, Ekstedt M, Kechagias S. Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms. PLoS One 2016;11:e0167776. [PMID: 27936091 DOI: 10.1371/journal.pone.0167776] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
82 Nguyen-khac E. Résultats et place du Fibroscan® dans le diagnostic non invasif de la fibrose hépatique. La Revue de Médecine Interne 2007;28:94-102. [DOI: 10.1016/j.revmed.2006.10.329] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
83 Sporea I, Popescu A, Sirli R. Why, who and how should perform liver biopsy in chronic liver diseases. World J Gastroenterol 2008; 14(21): 3396-3402 [PMID: 18528937 DOI: 10.3748/wjg.14.3396] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 49] [Article Influence: 4.0] [Reference Citation Analysis]
84 Shaheen AAM, Wan AF, Myers RP. FibroTest and FibroScan for the Prediction of Hepatitis C-Related Fibrosis: A Systematic Review of Diagnostic Test Accuracy. Am J Gastroenterology 2007;102:2589-600. [DOI: 10.1111/j.1572-0241.2007.01466.x] [Cited by in Crossref: 233] [Cited by in F6Publishing: 219] [Article Influence: 15.5] [Reference Citation Analysis]
85 Gangadharan B, Bapat M, Rossa J, Antrobus R, Chittenden D, Kampa B, Barnes E, Klenerman P, Dwek RA, Zitzmann N. Discovery of novel biomarker candidates for liver fibrosis in hepatitis C patients: a preliminary study. PLoS One 2012;7:e39603. [PMID: 22761838 DOI: 10.1371/journal.pone.0039603] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
86 Lefton HB, Rosa A, Cohen M. Diagnosis and Epidemiology of Cirrhosis. Medical Clinics of North America 2009;93:787-99. [DOI: 10.1016/j.mcna.2009.03.002] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 4.5] [Reference Citation Analysis]
87 Smith JO, Sterling RK. Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Alimentary Pharmacology & Therapeutics 2009;30:557-76. [DOI: 10.1111/j.1365-2036.2009.04062.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 86] [Article Influence: 6.6] [Reference Citation Analysis]
88 Dioguardi N, Grizzi F, Franceschini B, Bossi P, Russo C. Liver fibrosis and tissue architectural change measurement using fractal-rectified metrics and Hurst’s exponent. World J Gastroenterol 2006; 12(14): 2187-2194 [PMID: 16610019 DOI: 10.3748/wjg.v12.i14.2187] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
89 Bourliere M, Penaranda G, Renou C, Botta-Fridlund D, Tran A, Portal I, Lecomte L, Castellani P, Rosenthal-Allieri MA, Gerolami R, Ouzan D, Deydier R, Degott C, Halfon P. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. J Viral Hepat. 2006;13:659-670. [PMID: 16970597 DOI: 10.1111/j.1365-2893.2006.00736.x] [Cited by in Crossref: 96] [Cited by in F6Publishing: 90] [Article Influence: 6.0] [Reference Citation Analysis]
90 Snyder N, Gajula L, Xiao SY, Grady J, Luxon B, Lau DT, Soloway R, Petersen J. APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C. J Clin Gastroenterol. 2006;40:535-542. [PMID: 16825937 DOI: 10.1097/00004836-200607000-00013] [Cited by in Crossref: 81] [Cited by in F6Publishing: 74] [Article Influence: 5.1] [Reference Citation Analysis]
91 Zvibel I, Halfon P, Fishman S, Penaranda G, Leshno M, Or AB, Halpern Z, Oren R. Syndecan 1 (CD138) serum levels: a novel biomarker in predicting liver fibrosis stage in patients with hepatitis C. Liver Int 2009;29:208-12. [PMID: 18694404 DOI: 10.1111/j.1478-3231.2008.01830.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
92 Albanis E, Friedman SL. Diagnosis of hepatic fibrosis in patients with chronic hepatitis C. Clin Liver Dis. 2006;10:821-833. [PMID: 17164119 DOI: 10.1016/j.cld.2006.08.027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
93 Guéchot J. [Noninvasive assessment of liver fibrosis in patients with chronic hepatitis virus C]. Presse Med. 2006;35:1317-1326. [PMID: 16969327 DOI: 10.1016/s0755-4982(06)74811-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
94 Boas FE, Brown KT, Ziv E, Yarmohammadi H, Sofocleous CT, Erinjeri JP, Harding JJ, Solomon SB. Aspirin Is Associated With Improved Liver Function After Embolization of Hepatocellular Carcinoma. AJR Am J Roentgenol 2019;213:1-7. [PMID: 31120783 DOI: 10.2214/AJR.18.20846] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
95 Armutcu F, Akyol S, Ucar F, Erdogan S, Akyol O. Markers in Nonalcoholic Steatohepatitis. Elsevier; 2013. pp. 67-125. [DOI: 10.1016/b978-0-12-407680-8.00004-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Fang ZY, Zhang GS, Liu B, Meng DM. Non-invasive diagnosis of hepatitis B virus-related cirrhosis. Shijie Huaren Xiaohua Zazhi 2016; 24(29): 4092-4101 [DOI: 10.11569/wcjd.v24.i29.4092] [Reference Citation Analysis]
97 Bellan M, Castello LM, Pirisi M. Candidate Biomarkers of Liver Fibrosis: A Concise, Pathophysiology-oriented Review. J Clin Transl Hepatol 2018;6:317-25. [PMID: 30271745 DOI: 10.14218/JCTH.2018.00006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
98 Ippolito DL, Abdulhameed MDM, Tawa GJ, Baer CE, Permenter MG, Mcdyre BC, Dennis WE, Boyle MH, Hobbs CA, Streicker MA, Snowden BS, Lewis JA, Wallqvist A, Stallings JD. Gene Expression Patterns Associated With Histopathology in Toxic Liver Fibrosis. Toxicol Sci 2016;149:67-88. [DOI: 10.1093/toxsci/kfv214] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
99 Ziol M, Handra-luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, de Lédinghen V, Marcellin P, Dhumeaux D, Trinchet J, Beaugrand M. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41:48-54. [DOI: 10.1002/hep.20506] [Cited by in Crossref: 1018] [Cited by in F6Publishing: 961] [Article Influence: 56.6] [Reference Citation Analysis]
100 Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology. 2003;38:481-492. [PMID: 12883493 DOI: 10.1053/jhep.2003.50319] [Cited by in Crossref: 181] [Cited by in F6Publishing: 168] [Article Influence: 9.5] [Reference Citation Analysis]
101 Ngo Y, Munteanu M, Messous D, Charlotte F, Imbert-Bismut F, Thabut D, Lebray P, Thibault V, Benhamou Y, Moussalli J. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem. 2006;52:1887-1896. [PMID: 16931569 DOI: 10.1373/clinchem.2006.070961] [Cited by in Crossref: 170] [Cited by in F6Publishing: 167] [Article Influence: 10.6] [Reference Citation Analysis]
102 Lim AK, Patel N, Eckersley RJ, Fitzpatrick J, Crossey MM, Hamilton G, Goldin RD, Thomas HC, Vennart W, Cosgrove DO. A comparison of 31P magnetic resonance spectroscopy and microbubble-enhanced ultrasound for characterizing hepatitis c-related liver disease. J Viral Hepat. 2011;18:e530-e534. [PMID: 21914073 DOI: 10.1111/j.1365-2893.2011.01455.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
103 Vargas V. [Non-invasive methods for prediction of hepatic fibrosis in chronic hepatitis C]. Med Clin (Barc) 2005;124:775-7. [PMID: 15927104 DOI: 10.1157/13075850] [Reference Citation Analysis]
104 Gordon A, Bailey MJ, Gibson PR, Roberts SK. Comprehensive clinical assessment improves the accuracy of predicting cirrhosis in chronic hepatitis C: Predicting cirrhosis in hepatitis C. Journal of Gastroenterology and Hepatology 2005;20:825-32. [DOI: 10.1111/j.1440-1746.2005.03828.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
105 Weickert U, Buttmann A, Jakobs R, Schilling D, Eickhoff A, Riemann JF. Diagnosis of Liver Cirrhosis: A Comparison of Modified Ultrasound and Laparoscopy in 100 Consecutive Patients. Journal of Clinical Gastroenterology 2005;39:529-32. [DOI: 10.1097/01.mcg.0000165669.17649.20] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
106 Parkes J, Guha IN, Roderick P, Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol. 2006;44:462-474. [PMID: 16427156 DOI: 10.1016/j.jhep.2005.10.019] [Cited by in Crossref: 169] [Cited by in F6Publishing: 162] [Article Influence: 9.9] [Reference Citation Analysis]
107 Hermeziu B, Messous D, Fabre M, Munteanu M, Baussan C, Bernard O, Poynard T, Jacquemin E. Evaluation of FibroTest-ActiTest in children with chronic hepatitis C virus infection. Gastroenterol Clin Biol. 2010;34:16-22. [PMID: 19726147 DOI: 10.1016/j.gcb.2009.06.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
108 Portilla J, López-Burgos A, Saiz-De-La-Hoya-Zamácola P, Sánchez-Payá J, Bedía-Collantes M, Faraco-Atienzar I, Lissen E. [Utility of 2 biochemical models predictive of liver fibrosis grade in prison inmates with hepatitis C]. Gastroenterol Hepatol 2009;32:387-94. [PMID: 19477553 DOI: 10.1016/j.gastrohep.2009.01.176] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
109 Testa R, Testa E, Giannini E, Borro P, Milazzo S, Isola L, Ceppa P, Lantieri PB, Risso D. Noninvasive ratio indexes to evaluate fibrosis staging in chronic hepatitis C: role of platelet count/spleen diameter ratio index. J Intern Med. 2006;260:142-150. [PMID: 16882278 DOI: 10.1111/j.1365-2796.2006.01673.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
110 Raftopoulos SC, George J, Bourliere M, Rossi E, de Boer WB, Jeffrey GP, Bulsara M, Speers DJ, Macquillan G, Ching HLI, Kontorinis N, Cheng W, Flexman J, Fermoyle S, Rigby P, Walsh L, Mcleod D, Adams LA. Comparison of noninvasive models of fibrosis in chronic hepatitis B. Hepatol Int 2012;6:457-67. [DOI: 10.1007/s12072-011-9296-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
111 Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M;  APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317-1325. [PMID: 16729309 DOI: 10.1002/hep.21178] [Cited by in Crossref: 1954] [Cited by in F6Publishing: 1862] [Article Influence: 122.1] [Reference Citation Analysis]
112 Rosenthal-Allieri MA, Peritore ML, Tran A, Halfon P, Benzaken S, Bernard A. Analytical variability of the Fibrotest proteins. Clin Biochem. 2005;38:473-478. [PMID: 15820779 DOI: 10.1016/j.clinbiochem.2004.12.012] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
113 Mooney P, Hayes P, Smith K. The putative use of alpha-1-acid glycoprotein as a non-invasive marker of fibrosis. Biomed Chromatogr 2006;20:1351-8. [PMID: 17004233 DOI: 10.1002/bmc.704] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
114 Gonzalez HC, Jafri SM, Gordon SC. Role of Liver Biopsy in the Era of Direct-Acting Antivirals. Curr Gastroenterol Rep 2013;15. [DOI: 10.1007/s11894-012-0307-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
115 Lok AS, Wai C. Reply:. Hepatology 2004;39:863-863. [DOI: 10.1002/hep.20145] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
116 Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJ;  European Liver Fibrosis Group. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004;127:1704-1713. [PMID: 15578508 DOI: 10.1053/j.gastro.2004.08.052] [Cited by in Crossref: 687] [Cited by in F6Publishing: 628] [Article Influence: 40.4] [Reference Citation Analysis]
117 Shire NJ, Rao MB, Succop P, Buncher CR, Andersen JA, Butt AA, Chung RT, Sherman KE. Improving noninvasive methods of assessing liver fibrosis in patients with hepatitis C virus/human immunodeficiency virus co-infection. Clin Gastroenterol Hepatol. 2009;7:471-480, 480.e1-2. [PMID: 19268724 DOI: 10.1016/j.cgh.2008.12.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
118 Islam S, Antonsson L, Westin J, Lagging M. Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scand J Gastroenterol. 2005;40:867-872. [PMID: 16109665 DOI: 10.1080/00365520510015674] [Cited by in Crossref: 101] [Cited by in F6Publishing: 91] [Article Influence: 5.9] [Reference Citation Analysis]
119 Shah AG, Smith PG, Sterling RK. Comparison of FIB-4 and APRI in HIV-HCV coinfected patients with normal and elevated ALT. Dig Dis Sci 2011;56:3038-44. [PMID: 21526398 DOI: 10.1007/s10620-011-1710-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
120 Baranova A, Lal P, Birerdinc A, Younossi ZM. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol. 2011;11:91. [PMID: 21849046 DOI: 10.1186/1471-230x-11-91] [Cited by in Crossref: 181] [Cited by in F6Publishing: 78] [Article Influence: 16.5] [Reference Citation Analysis]
121 Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, Ratziu V, Mercadier A, Benhamou Y, Hainque B. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol. 2004;3:8. [PMID: 15387887 DOI: 10.1186/1476-5926-3-8] [Cited by in Crossref: 239] [Cited by in F6Publishing: 247] [Article Influence: 13.3] [Reference Citation Analysis]
122 Sökücü S, Gökçe S, Güllüoğlu M, Aydoğan A, Celtik C, Durmaz O. The role of the non-invasive serum marker FibroTest-ActiTest in the prediction of histological stage of fibrosis and activity in children with naïve chronic hepatitis B infection. Scand J Infect Dis 2010;42:699-703. [PMID: 20429710 DOI: 10.3109/00365541003774616] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
123 Macías J, Girón-González JA, González-Serrano M, Merino D, Cano P, Mira JA, Arizcorreta-Yarza A, Ruíz-Morales J, Lomas-Cabeza JM, García-García JA. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut. 2006;55:409-414. [PMID: 16118349 DOI: 10.1136/gut.2005.065904] [Cited by in Crossref: 94] [Cited by in F6Publishing: 87] [Article Influence: 5.5] [Reference Citation Analysis]
124 Trinchet JC, Grando-Lemaire V. [Diagnosis of cirrhosis]. Gastroenterol Clin Biol 2004;28:D121-8. [PMID: 15213672 DOI: 10.1016/s0399-8320(04)94996-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
125 Sporea I, Şirli R, Popescu A, Bota S, Badea R, Lupşor M, Focşa M, Dănilă M. Is it better to use two elastographic methods for liver fibrosis assessment? World J Gastroenterol 2011; 17(33): 3824-3829 [PMID: 21987625 DOI: 10.3748/wjg.v17.i33.3824] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
126 Halfon P, Munteanu M, Poynard T. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin Biol. 2008;32:22-39. [PMID: 18973844 DOI: 10.1016/s0399-8320(08)73991-5] [Cited by in Crossref: 77] [Cited by in F6Publishing: 26] [Article Influence: 5.9] [Reference Citation Analysis]
127 Cho HJ, Kim SS, Ahn SJ, Park JH, Kim DJ, Kim YB, Cho SW, Cheong JY. Serum transferrin as a liver fibrosis biomarker in patients with chronic hepatitis B. Clin Mol Hepatol. 2014;20:347-354. [PMID: 25548740 DOI: 10.3350/cmh.2014.20.4.347] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
128 Poynard T, Munteanu M, Imbert-bismut F, Charlotte F, Thabut D, Le Calvez S, Messous D, Thibault V, Benhamou Y, Moussalli J, Ratziu V. Prospective Analysis of Discordant Results between Biochemical Markers and Biopsy in Patients with Chronic Hepatitis C. Clinical Chemistry 2004;50:1344-55. [DOI: 10.1373/clinchem.2004.032227] [Cited by in Crossref: 216] [Cited by in F6Publishing: 213] [Article Influence: 12.0] [Reference Citation Analysis]
129 Martínez-Castillo M, Rosique-Oramas D, Medina-Avila Z, Pérez-Hernández JL, Higuera-De la Tijera F, Santana-Vargas D, Montalvo-Jave EE, Sanchez-Avila F, Torre A, Kershenobich D, Gutierrez-Reyes G. Differential production of insulin-like growth factor-binding proteins in liver fibrosis progression. Mol Cell Biochem 2020;469:65-75. [PMID: 32301061 DOI: 10.1007/s11010-020-03728-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
130 Rosenthal-allieri MA, Tran A, Halfon P, Imbert-bismut F, Munteanu M, Messous D, Peritore M, Poynard T, Bernard A. Optimal correlation between different instruments for Fibrotest-Actitest protein measurement in patients with chronic hepatitis C. Gastroentérologie Clinique et Biologique 2007;31:815-21. [DOI: 10.1016/s0399-8320(07)73971-4] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
131 Sterling RK, Lyons CD, Stravitz RT, Luketic VA, Sanyal AJ, Carr ME, Smith TJ, Hackney MH, Contos MJ, Mills SA, Kuhn JG, Nolte ME, Shiffman ML. Percutaneous liver biopsy in adult haemophiliacs with hepatitis C virus: safety of outpatient procedure and impact of human immunodeficiency virus coinfection on the spectrum of liver disease. Haemophilia 2007;13:164-71. [DOI: 10.1111/j.1365-2516.2006.01322.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
132 Leroy V, Monier F, Bottari S, Trocme C, Sturm N, Hilleret M, Morel F, Zarski J. Circulating Matrix Metalloproteinases 1, 2, 9 and Their Inhibitors TIMP-1 and TIMP-2 as Serum Markers of Liver Fibrosis in Patients With Chronic Hepatitis C: Comparison With PIIINP and Hyaluronic Acid. Am J Gastroenterol 2004;99:271-9. [DOI: 10.1111/j.1572-0241.2004.04055.x] [Cited by in Crossref: 168] [Cited by in F6Publishing: 151] [Article Influence: 9.3] [Reference Citation Analysis]
133 Park SH, Bang CS, Kim DJ. Biomarkers in HCV Infection. Adv Clin Chem 2015;70:131-96. [PMID: 26231487 DOI: 10.1016/bs.acc.2015.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
134 Grady B, van den Berg C, van der Helm J, Schinkel J, Coutinho R, Krol A, Prins M. No impact of hepatitis C virus infection on mortality among drug users during the first decade after seroconversion. Clin Gastroenterol Hepatol 2011;9:786-792.e1. [PMID: 21699803 DOI: 10.1016/j.cgh.2011.05.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
135 Denzer U, Arnoldy A, Kanzler S, Galle PR, Dienes HP, Lohse AW. Prospective randomized comparison of minilaparoscopy and percutaneous liver biopsy: diagnosis of cirrhosis and complications. J Clin Gastroenterol. 2007;41:103-110. [PMID: 17198072 DOI: 10.1097/01.mcg.0000225612.86846.82] [Cited by in Crossref: 56] [Cited by in F6Publishing: 43] [Article Influence: 3.7] [Reference Citation Analysis]
136 Arain SA, Jamal Q, Omair A. "Liverscore" is predictive of both liver fibrosis and activity in chronic hepatitis C. World J Gastroenterol 2011; 17(41): 4607-4613 [PMID: 22147967 DOI: 10.3748/wjg.v17.i41.4607] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
137 Matta B, Lee TH, Patel K. Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV. Curr HIV/AIDS Rep 2016;13:279-88. [PMID: 27485838 DOI: 10.1007/s11904-016-0329-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
138 Varaut A, Fontaine H, Serpaggi J, Verkarre V, Vallet-pichard A, Nalpas B, Imbertbismuth F, Lebray P, Pol S. Diagnostic Accuracy of the Fibrotest in Hemodialysis and Renal Transplant Patients with Chronic Hepatitis C Virus: . Transplantation 2005;80:1550-5. [DOI: 10.1097/01.tp.0000183399.85804.02] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
139 Moreno S, García-Samaniego J, Moreno A, Ortega E, Pineda JA, del Romero J, Tural C, von Wichmann MA, Berenguer J, Castro A. Noninvasive diagnosis of liver fibrosis in patients with HIV infection and HCV/HBV co-infection. J Viral Hepat. 2009;16:249-258. [PMID: 19215579 DOI: 10.1111/j.1365-2893.2009.01088.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
140 Attallah AM, Abdallah SO, Attallah AA, Omran MM, Farid K, Nasif WA, Shiha GE, Abdel-aziz AF, Rasafy N, Shaker YM. Diagnostic value of fibronectin discriminant score for predicting liver fibrosis stages in chronic hepatitis C virus patients. Annals of Hepatology 2013;12:44-53. [DOI: 10.1016/s1665-2681(19)31384-5] [Cited by in Crossref: 21] [Article Influence: 2.3] [Reference Citation Analysis]
141 Kamal S, Abdelhakam S, Ghoraba D, Mohsen MA, Salam AA, Hassan H, Nabeigh L. The Course of Hepatitis C Infection and Response to Anti-viral Therapy in Patients with Thalassemia major and Hepatitis C Infection: A Longitudinal, Prospective Study. Mediterr J Hematol Infect Dis 2019;11:e2019060. [PMID: 31700585 DOI: 10.4084/MJHID.2019.060] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
142 Gressner OA, Beer N, Jodlowski A, Gressner AM. Impact of quality control accepted inter-laboratory variations on calculated Fibrotest/Actitest scores for the non-invasive biochemical assessment of liver fibrosis. Clinica Chimica Acta 2009;409:90-5. [DOI: 10.1016/j.cca.2009.09.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
143 Pinzani M, Rombouts K, Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol. 2005;42 Suppl:S22-S36. [PMID: 15777570 DOI: 10.1016/j.jhep.2004.12.008] [Cited by in Crossref: 163] [Cited by in F6Publishing: 147] [Article Influence: 9.1] [Reference Citation Analysis]
144 Thuluvath PJ, Krok KL. Noninvasive Markers of Fibrosis for Longitudinal Assessment of Fibrosis in Chronic Liver Disease: Are They Ready for Prime Time? Am J Gastroenterol 2006;101:1497-9. [DOI: 10.1111/j.1572-0241.2005.00304.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
145 Eulenberg VM, Lidbury JA. Hepatic Fibrosis in Dogs. J Vet Intern Med. 2018;32:26-41. [PMID: 29194760 DOI: 10.1111/jvim.14891] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
146 Poynard T. [The Fibrotest is an ethical choice because it is a cost-effective and anti-inflationistic test. Response to Jean Louis Payen and Jean Marie Combis]. Gastroenterol Clin Biol 2004;28:929-31. [PMID: 15523238 DOI: 10.1016/s0399-8320(04)95166-4] [Reference Citation Analysis]
147 Zator ZA, Chung RT. After the cure: management of HCV after achievement of SVR. Curr HIV/AIDS Rep 2013;10:428-35. [PMID: 24218111 DOI: 10.1007/s11904-013-0181-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
148 Colli A, Colucci A, Paggi S, Fraquelli M, Massironi S, Andreoletti M, Michela V, Conte D. Accuracy of a predictive model for severe hepatic fibrosis or cirrhosis in chronic hepatitis C. World J Gastroenterol 2005;11:7318-22. [PMID: 16437635 DOI: 10.3748/wjg.v11.i46.7318] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
149 Naveau S, Raynard B, Ratziu V, Abella A, Imbert-Bismut F, Messous D, Beuzen F, Capron F, Thabut D, Munteanu M. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol. 2005;3:167-174. [PMID: 15704051 DOI: 10.1016/s1542-3565(04)00625-1] [Cited by in Crossref: 97] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
150 Poynard T, Imbert-bismut F, Munteanu M, Ratziu V. FibroTest-FibroSURE™: towards a universal biomarker of liver fibrosis? Expert Review of Molecular Diagnostics 2014;5:15-21. [DOI: 10.1586/14737159.5.1.15] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.9] [Reference Citation Analysis]
151 Denzer UW, Lüth S. Non-invasive diagnosis and monitoring of liver fibrosis and cirrhosis. Best Pract Res Clin Gastroenterol 2009;23:453-60. [PMID: 19505671 DOI: 10.1016/j.bpg.2009.03.002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
152 Younossi ZM, Noureddin M, Bernstein D, Kwo P, Russo M, Shiffman ML, Younes Z, Abdelmalek M. Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. Am J Gastroenterol 2021;116:254-62. [PMID: 33284184 DOI: 10.14309/ajg.0000000000001054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
153 Aloise DM, Izquierdo G. Uncertainty of Liver Cirrhosis Diagnosis and Use of Elastography. Cureus 2021;13:e18411. [PMID: 34725628 DOI: 10.7759/cureus.18411] [Reference Citation Analysis]
154 Huang Z, Chen X, Zhao Q, Zheng Y, Peng L, Gao Z, Zhao Z. An albumin, collagen IV, and longitudinal diameter of spleen scoring system superior to APRI for assessing liver fibrosis in chronic hepatitis B patients. International Journal of Infectious Diseases 2015;31:18-22. [DOI: 10.1016/j.ijid.2014.10.030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
155 Verslype C. EVALUATION OF ABNORMAL LIVER-ENZYME RESULTS IN ASYMPTOMATIC PATIENTS. Acta Clinica Belgica 2014;59:285-9. [DOI: 10.1179/acb.2004.042] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
156 Bourlière M, Pénaranda G, Adhoute X, Oules V, Castellani P. Combining non-invasive methods for assessment of liver fibrosis. Gastroentérologie Clinique et Biologique 2008;32:73-9. [DOI: 10.1016/s0399-8320(08)73996-4] [Cited by in Crossref: 9] [Article Influence: 0.6] [Reference Citation Analysis]
157 Ceylan B, Fincanci M, Yardimci C, Eren G, Tözalgan Ü, Müderrisoğlu C, Paşaoğlu E. Can mean platelet volume determine the severity of liver fibrosis or inflammation in patients with chronic hepatitis B? Eur J Gastroenterol Hepatol 2013;25:606-12. [PMID: 23325286 DOI: 10.1097/MEG.0b013e32835d08da] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
158 Castera L. Assessing liver fibrosis. Expert Rev Gastroenterol Hepatol. 2008;2:541-552. [PMID: 19072402 DOI: 10.1586/17474124.2.4.541] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
159 Stauber RE, Lackner C. Noninvasive diagnosis of hepatic fibrosis in chronic hepatitis C. World J Gastroenterol 2007; 13(32): 4287-4294 [PMID: 17708599 DOI: 10.3748/wjg.v13.i32.4287] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
160 Gangadharan B, Antrobus R, Chittenden D, Rossa J, Bapat M, Klenerman P, Barnes E, Dwek RA, Zitzmann N. New approaches for biomarker discovery: the search for liver fibrosis markers in hepatitis C patients. J Proteome Res. 2011;10:2643-2650. [PMID: 21410221 DOI: 10.1021/pr101077c] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]